Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Companies Reveal Likely EU Review Outcomes Against EMA Advice

Executive Summary

The European Medicines Agency asks companies to wait until they know for certain whether their marketing authorization applications will be approved or not before making any public announcement. Despite this, some companies go public as soon as they hear an early, but non-binding, verdict. The Pink Sheet looks at the issue of “trend votes” and at the companies who decide not to wait.


Related Content

Two Orphans And An Avastin Biosimilar Among EU Approval Recommendations
CHMP Delays Review of Portola's Ondexxya; Who Will Pass Muster?
Aimovig And Tegsedi In Raft Of Products To Get EMA Thumbs up
Six New Drugs Get EMA Nod, Radius and Portola To Fight Rejections
Clovis Confident, Portola Not: CHMP Decides On EU Marketing Applications
Five Drugs Set For EU Approval, Including Two Orphans
EU Delays For Portola As CHMP Trend Votes Go Good And Bad
Zero Success For Companies Appealing Negative CHMP Opinions In EU Last Year


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts